Related Experiment Video
Updated: Dec 29, 2025
Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
Published on: January 28, 2020
Beta-Blockers, Calcium Channel Blockers, and Mortality in Stable Coronary Artery Disease
Jose B Cruz Rodriguez1, Haider Alkhateeb2
1Division of Cardiovascular Diseases, Department of Internal Medicine, Texas Tech University Health Sciences Center, 4800 Alberta Avenue, El Paso, TX, 79905, USA. Benjamin.cruz@ttuhsc.edu.
Insights
Beta-blockers (BB) reduce mortality in stable coronary artery disease (SCAD) patients within one year post-myocardial infarction (MI). Calcium channel blockers (CCB) effectively treat angina but do not offer survival benefits in SCAD.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Stable coronary artery disease (SCAD) management aims to improve symptoms and long-term outcomes.
- Calcium channel blockers (CCB) and beta-blockers (BB) are frequently used antianginal agents.
Purpose of the Study:
- To review current clinical evidence on CCB and BB in SCAD patients.
- To assess the impact of CCB and BB on mortality in SCAD.
Main Methods:
- Review of existing clinical evidence and trial data.
- Analysis of mortality outcomes associated with CCB and BB use in SCAD.
Main Results:
- Beta-blockers (BB) show a 5-year all-cause mortality benefit in SCAD patients within one year post-myocardial infarction (MI).
- Calcium channel blockers (CCB) are effective antianginals but have not demonstrated a mortality benefit in SCAD.
- BB and CCB efficacy as antianginals is established, with selection based on patient presentation and comorbidities.
Conclusions:
- Beta-blockers (BB) are the only agents demonstrating survival benefit in SCAD, particularly in the first year post-MI.
- Treatment decisions for SCAD should consider both antianginal efficacy and mortality impact, favoring BB for survival benefits in specific patient groups.
Purpose Of Review:
To examine the current clinical evidence behind the use of calcium channel blockers (CCB) and beta-blockers (BB) for the treatment of patients with stable coronary artery disease (SCAD) and their effect on mortality.
Recent Findings:
Current evidence suggests that BB use as a first line antianginal medication is associated with lower 5-year all-cause mortality only in patients who had MI within a year. This could be driven due to their effects reducing the sympathetic neuro-hormonal activation of more acutely ill patients. The use of CCB as an antianginal therapy, although proven effective in multiple trials both as monotherapy and combined with other agents, has not shown mortality benefit. Both BB and CCB are effective antianginals, and the selection among them depends on the patient clinical presentation and comorbidities. BB are the only ones that have shown survival benefit in SCAD, particularly the first year post-MI.
More Related Videos
07:42Contractions of Human-iPSC-derived Cardiomyocyte Syncytia Measured with a Ca-sensitive Fluorescent Dye in Temperature-controlled 384-well Plates
Published on: October 18, 2018
10:53Isolation of Human Atrial Myocytes for Simultaneous Measurements of Ca2+ Transients and Membrane Currents
Published on: July 3, 2013
Related Concept Videos
01:22Heart Failure Drugs: β-Blockers
01:18Antihypertensive Drugs: Action of Calcium Channel Blockers
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
01:20Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
01:28Antihypertensive Drugs: Types of β-Blockers